Xbrane Biopharma AB (FRA:7XB0) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7XB0 Xbrane Biopharma AB FRA:7XB0
71 GF Score
Price €0.77
GF Value €0.49
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:7XB0
71GF Score
Xbrane Biopharma AB FRA:7XB0
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xbrane Biopharma AB (FRA:7XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of €0.77 is trading 57.6% above its estimated GF Value™ of €0.49.

Key valuation signals for FRA:7XB0:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.49 vs. price of €0.77 (57.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xbrane Biopharma AB Business Description

Other Exchanges XBRANE:Sweden
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for FRA:7XB0

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€0.49
GF Value